(Q36754874)

16 August 2017

title

Prenatal screening for fetal aneuploidy. (English)

1 reference

16 August 2017

Anne M Summers

1

1 reference

16 August 2017

Sylvie Langlois

2

1 reference

16 August 2017

Phil Wyatt

3

1 reference

16 August 2017

R Douglas Wilson

4

1 reference

16 August 2017

Society of Obstetricians and Gynaecologists of Canada

5

1 reference

16 August 2017

publication date

1 February 2007

1 reference

Journal of Obstetrics and Gynaecology Canada

16 August 2017

published in

1 reference

16 August 2017

volume

29

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

146-179

1 reference

Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: Implications for prenatal screening and genetic counseling

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Sonographic markers of fetal trisomies: second trimester.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Second trimester ultrasound screening for chromosomal abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

A cost-effectiveness analysis of prenatal screening strategies for Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First-trimester or second-trimester screening, or both, for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Antenatal screening for Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Women and health care professionals' preferences for Down's Syndrome screening tests: a conjoint analysis study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First-trimester screening for trisomies 21 and 18

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First-trimester free beta (hCG) screening for Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Maternal serum screening for Down's syndrome in early pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Screening of maternal serum for fetal Down's syndrome in the first trimester

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Prenatal screening for Down's syndrome using inhibin-A as a serum marker

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Integrated screening for Down's syndrome based on tests performed during the first and second trimesters

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Prenatal screening for Down's syndrome--a search for the family's values

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Practical strategies in contingent sequential screening for Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Comparing three screening strategies for combining first- and second-trimester Down syndrome markers

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Sequential and contingent prenatal screening for Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Contingent screening for Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Sequential pathways of testing after first-trimester screening for trisomy 21.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Repeated measures screening for Down's Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: A validation study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Cross-trimester marker ratios in prenatal screening for Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Prenatal screening for trisomy 18 in the second trimester

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Second-trimester maternal serum progesterone levels in Turner syndrome with and without hydrops and in trisomy 18

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Prenatal diagnosis of trisomy 18 at the 10-14-week ultrasound scan

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Triploidy identified through second-trimester serum screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Second-trimester maternal serum analyte levels associated with fetal trisomy 13

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Inhibin A and non-Down syndrome aneuploidy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Low or absent unconjugated estriol in pregnancy: an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Evaluation of the lemon and banana signs in one hundred thirty fetuses with open spina bifida

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Minor sonographic signs of trisomy 21 at 15-20 weeks' gestation in fetuses born without malformations: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

The association between isolated fetal echogenic cardiac foci on second-trimester ultrasound scan and trisomy 21 in low-risk unselected women.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

The "genetic sonogram": comparison of the index scoring system with the age-adjusted US risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

An 8-center study to evaluate the utility of mid-term genetic sonograms among high-risk pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First-trimester nasal bone evaluation for aneuploidy in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Intra- and interoperator variability in fetal nasal bone assessment at 11-14 weeks of gestation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Refinements in managing maternal weight adjustment for interpreting prenatal screening results

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Co-variables in first trimester maternal serum screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Effect of allowing for ethnic group in prenatal screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Maternal serum marker medians in Aboriginal Canadian women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Influence of ethnic origin on nuchal translucency screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

The effect of ethnic origin on nuchal translucency at 10-14 weeks of gestation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Human chorionic gonadotropin and unconjugated oestriol measurements in insulin-dependent diabetic pregnant women being screened for fetal Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Down's syndrome screening marker levels following assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Maternal serum beta-HCG and alpha-fetoprotein concentrations in singleton pregnancies following assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Serum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

Nuchal translucency in pregnancies conceived after assisted reproduction technology

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932379-9

7 January 2021

10.1016/S1701-2163(16)32379-9

Identifiers

DOI

0 references

1 reference